Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Executive Summary
The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.
You may also be interested in...
Bausch Health Rises From Valeant's Simmering Ashes
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
Valeant Claims Progress, Asks Investors For Patience
The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.
Need a specific report? 1000+ reports available
Buy Reports